D'Ambrosio, Lorenzo, Touati, Nathan, Blay, Jean-Yves ORCID: 0000-0001-7190-120X, Grignani, Giovanni, Flippot, Ronan, Czarnecka, Anna M., Piperno-Neumann, Sophie, Martin-Broto, Javier ORCID: 0000-0001-7350-6916, Sanfilippo, Roberta, Katz, Daniela, Duffaud, Florence, Vincenzi, Bruno, Stark, Daniel P., Mazzeo, Filomena, Tuchscherer, Armin, Chevreau, Christine, Sherriff, Jenny, Estival, Anna, Litiere, Saskia, Sents, Ward, Ray-Coquard, Isabelle, Tolomeo, Francesco, Le Cesne, Axel, Rutkowski, Piotr, Stacchiotti, Silvia, Kasper, Bernd, Gelderblom, Hans and Gronchi, Alessandro (2020). Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cancer, 126 (11). S. 2637 - 2648. HOBOKEN: WILEY. ISSN 1097-0142

Full text not available from this repository.

Abstract

Background The optimal treatment for advanced leiomyosarcoma is still debated. Given histotype-specific prospective controlled data lacking, this study retrospectively evaluated doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone as first-line treatments for advanced/metastatic leiomyosarcoma treated at European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) sites. Methods The inclusion criteria were a confirmed histological diagnosis, treatment between January 2010 and December 2015, measurable disease (Response Evaluation Criteria in Solid Tumors 1.1), an Eastern Cooperative Oncology Group performance status <= 2, and an age >= 18 years. The endpoints were progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). PFS was analyzed with methods for interval-censored data. Patients were matched according to their propensity scores, which were estimated with a logistic regression model accounting for histology, grade, age, sex, performance status, tumor site, and tumor extent. Results Three hundred three patients from 18 EORTC-STBSG sites were identified. One hundred seventeen (39%) received doxorubicin plus dacarbazine, 71 (23%) received doxorubicin plus ifosfamide, and 115 (38%) received doxorubicin. In the 2:1:2 propensity score-matched population (205 patients), the estimated median PFS was 9.2 months (95% confidence interval [CI], 5.2-9.7 months), 8.2 months (95% CI, 5.2-10.1 months), and 4.8 months (95% CI, 2.3-6.0 months) with ORRs of 30.9%, 19.5%, and 25.6% for doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, and doxorubicin alone, respectively. PFS was significantly longer with doxorubicin plus dacarbazine versus doxorubicin (hazard ratio [HR], 0.72; 95% CI, 0.52-0.99). Doxorubicin plus dacarbazine was associated with longer OS (median, 36.8 months; 95% CI, 27.9-47.2 months) in comparison with both doxorubicin plus ifosfamide (median, 21.9 months; 95% CI, 16.7-33.4 months; HR, 0.65; 95% CI, 0.40-1.06) and doxorubicin (median, 30.3 months; 95% CI, 21.0-36.3 months; HR, 0.66; 95% CI, 0.43-0.99). Adjusted analyses retained an effect for PFS but not for OS. None of the factors selected for multivariate analysis had a significant interaction with the received treatment for both PFS and OS. Conclusions This is the largest retrospective study of first-line treatment for advanced leiomyosarcoma. In the propensity score-matched population, doxorubicin and dacarbazine showed favorable activity in terms of both ORR and PFS and warrants further evaluation in prospective trials.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
D'Ambrosio, LorenzoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Touati, NathanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Blay, Jean-YvesUNSPECIFIEDorcid.org/0000-0001-7190-120XUNSPECIFIED
Grignani, GiovanniUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Flippot, RonanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Czarnecka, Anna M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Piperno-Neumann, SophieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Martin-Broto, JavierUNSPECIFIEDorcid.org/0000-0001-7350-6916UNSPECIFIED
Sanfilippo, RobertaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Katz, DanielaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Duffaud, FlorenceUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vincenzi, BrunoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stark, Daniel P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mazzeo, FilomenaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tuchscherer, ArminUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chevreau, ChristineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sherriff, JennyUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Estival, AnnaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Litiere, SaskiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sents, WardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ray-Coquard, IsabelleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tolomeo, FrancescoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Le Cesne, AxelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rutkowski, PiotrUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stacchiotti, SilviaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kasper, BerndUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gelderblom, HansUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gronchi, AlessandroUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-332447
DOI: 10.1002/cncr.32795
Journal or Publication Title: Cancer
Volume: 126
Number: 11
Page Range: S. 2637 - 2648
Date: 2020
Publisher: WILEY
Place of Publication: HOBOKEN
ISSN: 1097-0142
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
RANDOMIZED PHASE-II; METASTATIC LIPOSARCOMA; ADVANCED UTERINE; SPANISH GROUP; OPEN-LABEL; TRABECTEDIN; CHEMOTHERAPY; MULTICENTER; GEMCITABINE; ADRIAMYCINMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/33244

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item